Systematic review of the effectiveness of non-pharmacological interventions to improve quality of life of people with dementia

Grants

Funding Acknowledgements

DB has received grant funding from NIDA and NIMH, National Institutes of Health, USA. GL and LT are each co-authors of one of the reviewed papers. GL has received funding from Lundbeck. HB is grant support/sponsored speaker or advisory board member of NHMRC, Australian Commonwealth Department of Health and Ageing, Pfizer, Eisai, Janssen, Novartis, Lundbeck, Lilly, Medivation, Sanofi, Prana (none relevant to this paper). CGL has received grant support (research or continuing education) from NIMH, NIA, Associated Jewish Federation of Baltimore, Weinberg Foundation, Forest, Glaxo-Smith-Kline, Eisai, Pfizer, Astra-Zeneca, Lilly, Ortho-McNeil, Bristol-Myers, Novartis, National Football League, and Elan; consultant/advisor for Astra-Zeneca, Glaxo-Smith Kline, Eisai, Novartis, Forest, Supernus, Adlyfe, Takeda, Wyeth, Lundbeck, Merz, Lilly, Pfizer, Genentech, Elan, NFL Players Association, NFL Benefits Office; honorarium or travel support from Pfizer, Forest, Glaxo-Smith Kline, Health Monitor. CK has undertaken paid lectures, advisory board membership, and received consultancy fees from several pharmaceutical companies including Lilly Lundbeck and Pfizer Eisai; grant funding from Lundbeck; expert testimony on behalf of GSK. PR has provided legal testimony for Janssen Pharmaceutica, and received grant support from NIMH and NIA.